Literature DB >> 23975230

Optimal control of nausea and vomiting with a three-drug antiemetic regimen with aprepitant in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX.

Nicola Silvestris1, Anna Elisabetta Brunetti, Marco Russano, Patrizia Nardulli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23975230     DOI： 10.1007/s00520-013-1944-y

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  3 in total

1.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

2.  Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials.

Authors:  Richard J Gralla; Ronald de Wit; Jorn Herrstedt; Alexandra D Carides; Juliana Ianus; Julie Guoguang-Ma; Judith K Evans; Kevin J Horgan
Journal:  Cancer       Date:  2005-08-15       Impact factor: 6.860

3.  Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.

Authors:  Sergio Poli-Bigelli; Jose Rodrigues-Pereira; Alexandra D Carides; Guoguang Julie Ma; Krista Eldridge; Anita Hipple; Judith K Evans; Kevin J Horgan; Francesca Lawson
Journal:  Cancer       Date:  2003-06-15       Impact factor: 6.860
  3 in total
  3 in total

1.  Reality of the emetogenic level of irinotecan.

Authors:  Maria-Angeles Garcia-Del-Barrio; Salvador Martin-Algarra; Azucena Aldaz Pastor
Journal:  Support Care Cancer       Date:  2018-04-21       Impact factor: 3.603

Review 2.  Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.

Authors:  Vanessa Piechotta; Anne Adams; Madhuri Haque; Benjamin Scheckel; Nina Kreuzberger; Ina Monsef; Karin Jordan; Kathrin Kuhr; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2021-11-16

Review 3.  Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: A critical update.

Authors:  Giuseppe Aprile; Karim Rihawi; Elisa De Carlo; Stephen T Sonis
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.